

Linezolid for the Treatment of Multidrug-Resistant, Gram-Positive Infections: Evidence from a Compassionate-Use Program

Clinical Infectious Diseases

36, 159-168

DOI: 10.1086/345744

Citation Report

#	ARTICLE	IF	CITATIONS
1	Linezolid in the treatment of vancomycin-resistant <i>Enterococcus faecium</i> in solid organ transplant recipients: report of a multicenter compassionate-use trial. <i>Transplant Infectious Disease</i> , 2003, 5, 121-125.	0.7	50
2	Basic pharmacodynamics of antibacterials with clinical applications to the use of β -lactams, glycopeptides, and linezolid. <i>Infectious Disease Clinics of North America</i> , 2003, 17, 479-501.	1.9	520
3	Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use Programme. <i>Clinical Pharmacokinetics</i> , 2003, 42, 1411-1423.	1.6	256
4	Antimicrobial strategies for the prevention and treatment of cardiovascular infections. <i>Current Opinion in Pharmacology</i> , 2003, 3, 464-469.	1.7	25
5	New therapeutic agents for resistant Gram-positive infections. <i>Expert Review of Anti-Infective Therapy</i> , 2003, 1, 655-665.	2.0	3
6	Safety and tolerability of linezolid. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 45ii-53.	1.3	121
7	Linezolid. <i>Paediatric Drugs</i> , 2003, 5, 419-429.	1.3	21
8	Linezolid Does Not Increase the Risk of Thrombocytopenia in Patients with Nosocomial Pneumonia: Comparative Analysis of Linezolid and Vancomycin Use. <i>Clinical Infectious Diseases</i> , 2003, 37, 1609-1616.	2.9	79
9	Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1824-1831.	1.4	168
10	Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. <i>Annals of Oncology</i> , 2003, 14, 795-801.	0.6	75
11	Population Pharmacokinetics of Linezolid in Patients Treated in a Compassionate-Use Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 548-553.	1.4	143
12	Linezolid for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> infections in children. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, S178-S185.	1.1	62
13	Linezolid for the treatment of complicated skin and skin structure infections in children. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, S172-S177.	1.1	49
14	Role of oral antimicrobial therapy in the management of osteomyelitis. <i>Current Opinion in Infectious Diseases</i> , 2003, 16, 515-519.	1.3	52
15	Safety and tolerability of linezolid in children. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, S193-S200.	1.1	76
16	Vancomycin-resistant <i>Enterococcus faecium</i> endocarditis in a premature infant successfully treated with linezolid. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, 1101-1103.	1.1	41
17	Severe bilateral optic neuritis associated with prolonged linezolid therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 1114-1115.	1.3	55
18	Cystic Fibrosis Diagnosed in a 38-Year-Old Man with Long-Standing HIV Infection. <i>Clinical Infectious Diseases</i> , 2004, 39, 438-439.	2.9	2

#	ARTICLE	IF	CITATIONS
19	Strongyloides stercoralis Infection as a Manifestation of Immune Restoration Syndrome. <i>Clinical Infectious Diseases</i> , 2004, 39, 439-440.	2.9	28
20	Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a caseâ€“control study. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 798-802.	1.3	80
21	Endocarditis Caused by <i>Staphylococcus aureus</i> with Reduced Susceptibility to Vancomycin. <i>Clinical Infectious Diseases</i> , 2004, 38, 1188-1191.	2.9	45
22	Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant <i>Enterococcus faecium</i> infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 646-649.	1.3	58
23	Causal Relationship between Neuropathy and Prolonged Linezolid Use. <i>Clinical Infectious Diseases</i> , 2004, 39, 439-439.	2.9	58
24	Treatment of Gram-positive bone and joint infection: authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 1159-1159.	1.3	12
25	Clinical-Use-Associated Decrease in Susceptibility of Vancomycin-Resistant <i>Enterococcus faecium</i> to Linezolid: a Comparison with Quinupristin-Dalfopristin. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3583-3585.	1.4	51
26	The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic-resistant organisms. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 405-414.	1.0	23
27	Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 971-981.	1.3	138
28	Antibiotics in the management of spinal postoperative wound infections. <i>Seminars in Spine Surgery</i> , 2004, 16, 174-181.	0.1	0
29	<i>Enterococcus faecalis</i> Resistant to Linezolid: Case Series and Review of the Literature. <i>Pharmacotherapy</i> , 2004, 24, 1225-1231.	1.2	39
30	Linezolid in the Treatment of Osteomyelitis: Results of Compassionate Use Experience. <i>Infection</i> , 2004, 32, 8-14.	2.3	109
31	Simple method for the assay of linezolid in Brain Heart Infusion broth by high-performance liquid chromatography. <i>Biomedical Chromatography</i> , 2004, 18, 1-5.	0.8	15
33	Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 345-355.	1.3	95
34	Linezolid-Associated Peripheral Neuropathy. <i>Mayo Clinic Proceedings</i> , 2004, 79, 927-930.	1.4	83
35	The Clinical Impact of Multiresistant Gram-Positive Microorganisms in Long-Term Care Facilities. <i>Journal of the American Medical Directors Association</i> , 2004, 5, 63-64.	1.2	2
36	Oxazolidinones: activity, mode of action, and mechanism of resistance. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 113-119.	1.1	298
37	Treatment with linezolid and rifampicin for 18 months for recurrent infection of a megaprosthesis in a patient with Ewing's sarcoma. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 628-630.	1.1	2

#	ARTICLE	IF	CITATIONS
38	Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections. <i>Clinical Pharmacokinetics</i> , 2004, 43, 925-942.	1.6	644
39	A review of linezolid: the first oxazolidinone antibiotic. <i>Expert Review of Anti-Infective Therapy</i> , 2004, 2, 51-59.	2.0	124
40	Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin. <i>Infectious Disease Clinics of North America</i> , 2004, 18, 651-668.	1.9	41
41	Peripheral neuropathy associated with prolonged use of linezolid. <i>Lancet Infectious Diseases</i> , The, 2004, 4, 528-531.	4.6	239
42	Clinical challenges of nosocomial infections caused by antibiotic-resistant pathogens in pediatrics. <i>Seminars in Pediatric Infectious Diseases</i> , 2004, 15, 21-29.	1.7	16
43	Antimicrobial resistance: is it really that bad?. <i>Seminars in Pediatric Infectious Diseases</i> , 2004, 15, 99-104.	1.7	4
44	Osteomyelitis. <i>Lancet</i> , The, 2004, 364, 369-379.	6.3	1,612
45	TREATMENT OF HEPATITIS C IN CHILDREN. <i>Pediatric Infectious Disease Journal</i> , 2004, 23, 257-258.	1.1	5
46	Update on the Use of Linezolid. <i>Pediatric Infectious Disease Journal</i> , 2004, 23, 955-956.	1.1	49
47	MANAGEMENT OF ACUTE HEMATOGENOUS OSTEOMYELITIS IN CHILDREN. <i>Pediatric Infectious Disease Journal</i> , 2004, 23, 255-257.	1.1	45
48	Clinical Experience With Linezolid in Conjunction With Wound Coverage Techniques for Skin and Soft-Tissue Infections and Postoperative Osteomyelitis. <i>Annals of Plastic Surgery</i> , 2004, 52, 385-390.	0.5	14
49	Approaches to vancomycin-resistant enterococci. <i>Current Opinion in Infectious Diseases</i> , 2004, 17, 541-547.	1.3	32
50	Recent advances in the treatment of infections due to resistant Staphylococcus aureus. <i>Current Opinion in Infectious Diseases</i> , 2004, 17, 549-555.	1.3	51
54	Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus. <i>Internal Medicine Journal</i> , 2005, 35, S3-S16.	0.5	134
56	Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2005, 24, 826-831.	1.3	32
57	Agents for the treatment of multidrug-resistant gram-positive endocarditis. <i>Current Infectious Disease Reports</i> , 2005, 7, 245-250.	1.3	1
58	Linezolid Contributed to Clostridium difficile Colitis with Fatal Outcome. <i>Infection</i> , 2005, 33, 155-157.	2.3	11
59	Probable Linezolid-Induced Pancytopenia. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2005, 16, 286-288.	0.7	11

#	ARTICLE	IF	CITATIONS
60	Linezolid induced toxic optic neuropathy. <i>British Journal of Ophthalmology</i> , 2005, 89, 1664-1665.	2.1	34
61	Safety of Newer Parenteral Antibiotics. <i>Clinical Infectious Diseases</i> , 2005, 41, S293-S302.	2.9	33
62	Severe staphylococcal knee arthritis responding favourably to linezolid, after glycopeptide-rifampicin failure: A case report and literature review. <i>Scandinavian Journal of Infectious Diseases</i> , 2005, 37, 513-517.	1.5	12
63	Intermittent exotropia increasing with near fixation: a "soft" sign of neurological disease. <i>British Journal of Ophthalmology</i> , 2005, 89, 1120-1122.	2.1	24
64	Pharmacokinetics and Pharmacodynamics of Linezolid in Obese Patients with Cellulitis. <i>Annals of Pharmacotherapy</i> , 2005, 39, 427-432.	0.9	77
65	Linezolid versus vancomycin for <i>Staphylococcus aureus</i> bacteraemia: pooled analysis of randomized studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 923-929.	1.3	172
66	Ultrahigh resolution optical coherence tomography of birdshot retinochoroidopathy. <i>British Journal of Ophthalmology</i> , 2005, 89, 1660-1661.	2.1	23
68	Delayed progressive visual loss following wrapping of bilateral clinoidal aneurysms: recovery of vision and improvement in neuroimaging during corticosteroid treatment. <i>British Journal of Ophthalmology</i> , 2005, 89, 1666-1668.	2.1	10
69	Endocarditis Due to Vancomycin-Resistant Enterococci: Case Report and Review of the Literature. <i>Clinical Infectious Diseases</i> , 2005, 41, 1134-1142.	2.9	68
70	Unilateral necrotising toxoplasmic retinochoroiditis as the main clinical manifestation of a peptide transporter (TAP) deficiency. <i>British Journal of Ophthalmology</i> , 2005, 89, 1661-1662.	2.1	18
71	Retinal changes in juvenile X linked retinoschisis using three dimensional optical coherence tomography. <i>British Journal of Ophthalmology</i> , 2005, 89, 1663-1664.	2.1	21
72	Infective Endocarditis. <i>Circulation</i> , 2005, 111, e394-434.	1.6	1,386
73	Visual loss may be due to silicone oil tamponade effect rather than silicone oil removal. <i>British Journal of Ophthalmology</i> , 2005, 89, 1667-1667.	2.1	10
74	Empiric Treatment of Nosocomial Intra-Abdominal Infections: A Focus on the Carbapenems. <i>Surgical Infections</i> , 2005, 6, 329-343.	0.7	22
75	Optometric referrals: towards a two way flow of information?. <i>British Journal of Ophthalmology</i> , 2005, 89, 1663-1663.	2.1	17
76	Visual loss following silicone oil removal. <i>British Journal of Ophthalmology</i> , 2005, 89, 1668-1668.	2.1	12
77	Visual loss after silicone oil removal. <i>British Journal of Ophthalmology</i> , 2005, 89, 1667-1668.	2.1	33
78	Scleral contact lenses are not optically inferior to corneal lenses. <i>British Journal of Ophthalmology</i> , 2005, 89, 1662-1663.	2.1	11

#	ARTICLE	IF	CITATIONS
79	Adult Osteomyelitis. <i>Infectious Disease Clinics of North America</i> , 2005, 19, 765-786.	1.9	150
80	Bone and Joint Infections in Children. <i>Pediatric Clinics of North America</i> , 2005, 52, 779-794.	0.9	206
81	Successful treatment of <i>Staphylococcus epidermidis</i> prosthetic valve endocarditis with linezolid after failure of treatment with oxacillin, gentamicin, rifampicin, vancomycin, and fusidic acid regimens. <i>Scandinavian Journal of Infectious Diseases</i> , 2005, 37, 173-176.	1.5	18
82	Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2260-2266.	1.4	408
84	New Drugs for Tuberculosis: Current Status and Future Prospects. <i>Clinics in Chest Medicine</i> , 2005, 26, 327-340.	0.8	64
85	Role of linezolid in the treatment of orthopedic infections. <i>Expert Review of Anti-Infective Therapy</i> , 2005, 3, 343-352.	2.0	10
86	Use of linezolid in children: an overview of recent advances. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 947-952.	2.0	8
88	Viridans group streptococci in blood culture isolates in a Swedish university hospital: antibiotic susceptibility and identification of erythromycin resistance genes. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 292-296.	1.1	24
89	Linezolid-Induced Inhibition of Mitochondrial Protein Synthesis. <i>Clinical Infectious Diseases</i> , 2006, 42, 1111-1117.	2.9	270
90	The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 56, 407-413.	0.8	7
92	Emergency Department Perspective on Methicillin-resistant <i>Staphylococcus aureus</i> . <i>Pediatric Emergency Care</i> , 2006, 22, 270-276.	0.5	2
93	Osteomyelitis: clinical update for practical guidelines. <i>Nuclear Medicine Communications</i> , 2006, 27, 645-660.	0.5	52
94	Evolving trends in infective endocarditis. <i>Clinical Microbiology and Infection</i> , 2006, 12, 5-12.	2.8	106
95	Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains. <i>Clinical Microbiology and Infection</i> , 2006, 12, 391-394.	2.8	33
96	Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) – a report of ten cases. <i>Journal of Infection</i> , 2006, 52, 92-96.	1.7	142
97	Infective endocarditis treated with linezolid: case report and literature review. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2006, 25, 202-204.	1.3	14
98	How best to deal with endocarditis. <i>Current Infectious Disease Reports</i> , 2006, 8, 14-22.	1.3	4
99	Early experience with linezolid for infections in orthopaedics. <i>Injury</i> , 2006, 37, 818-826.	0.7	26

#	ARTICLE	IF	CITATIONS
100	Bell's Palsy Associated with Linezolid Therapy: Case Report and Review of Neuropathic Adverse Events. <i>Pharmacotherapy</i> , 2006, 26, 1183-1189.	1.2	20
101	High-performance liquid chromatographic method for simple and rapid determination of linezolid in human plasma. <i>Biomedical Chromatography</i> , 2006, 20, 782-786.	0.8	36
102	The Effectiveness and Safety of Oral Linezolid as Primary or Secondary Treatment of Bloodstream Infections. <i>Infectious Diseases in Clinical Practice</i> , 2006, 14, 221-226.	0.1	3
103	Linezolid-associated toxic optic neuropathy. <i>Neurology</i> , 2006, 66, 595-598.	1.5	109
105	Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 279-287.	1.3	71
106	Community-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> : New Bug, Old Drugs. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1125-1133.	0.9	46
107	Guidelines for the prophylaxis and treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infections in the UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 589-608.	1.3	350
108	Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 273-280.	1.3	145
109	Good Clinical Outcomes but High Rates of Adverse Reactions during Linezolid Therapy for Serious Infections: a Proposed Protocol for Monitoring Therapy in Complex Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1599-1602.	1.4	132
110	Comparison of Testing Methods for Detection of Decreased Linezolid Susceptibility Due to G2576T Mutation of the 23S rRNA Gene in <i>Enterococcus faecium</i> and <i>Enterococcus faecalis</i> . <i>Journal of Clinical Microbiology</i> , 2006, 44, 1098-1100.	1.8	25
111	Oxazolidinone Antibiotics. , 2007, , 673-698.		1
112	Optimizing Therapy for Vancomycin-Resistant Enterococci (VRE). <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007, 28, 632-645.	0.8	53
113	Linezolid-induced optic neuropathy: a mitochondrial disorder?. <i>British Journal of Ophthalmology</i> , 2007, 91, 111-115.	2.1	78
114	Pharmacokinetic/Pharmacodynamic Factors Influencing Emergence of Resistance to Linezolid in an In Vitro Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1287-1292.	1.4	58
115	The role of vitamin B6 in the prevention of haematological toxic effects of linezolid in patients with cancer. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 421-424.	1.3	17
116	An Insight on Targets and Patented Drugs for Chemotherapy of Chagas Disease. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2007, 2, 19-51.	0.5	66
118	Zyvox® Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 59, 199-209.	0.8	41
119	LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 59, 309-317.	0.8	100

#	ARTICLE	IF	CITATIONS
121	Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Protocols. <i>Methods in Molecular Biology</i> , 2007, 391, v.	0.4	14
123	Infectious Diseases: Pharmacologic Treatment Options for Nosocomial Pneumonia Involving Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Annals of Pharmacotherapy</i> , 2007, 41, 235-244.	0.9	49
124	Antimicrobial therapy of <i>Staphylococcus aureus</i> bloodstream infection. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2505-2518.	0.9	12
125	Linezolid: effectiveness and safety for approved and off-label indications. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2381-2400.	0.9	32
126	Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections. <i>Current Medical Research and Opinion</i> , 2007, 23, 185-193.	0.9	25
127	Vancomycin-Resistant <i>Enterococcus</i> in Critical Care Areas. <i>Critical Care Nursing Clinics of North America</i> , 2007, 19, 69-75.	0.4	3
128	Treatment of Infections Caused by Resistant <i>Staphylococcus aureus</i> . <i>Methods in Molecular Biology</i> , 2007, 391, 227-258.	0.4	16
129	Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox® Annual Appraisal of Potency and Spectrum Study. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 295-301.	1.1	29
130	Haematological safety of long-term therapy with linezolid. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 480-483.	1.1	10
131	Zyvox. , 2007, , 157-171.		3
132	Linezolid in the Treatment of Implant-related Chronic Osteomyelitis. <i>Clinical Orthopaedics and Related Research</i> , 2007, 461, 40-43.	0.7	32
133	Antituberculosis drugs: Ten years of research. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 2479-2513.	1.4	441
134	Emerging Options for Treatment of Invasive, Multidrug-Resistant <i>Staphylococcus aureus</i> Infections. <i>Pharmacotherapy</i> , 2007, 27, 227-249.	1.2	99
135	Linezolid-Associated Peripheral and Optic Neuropathy, Lactic Acidosis, and Serotonin Syndrome. <i>Pharmacotherapy</i> , 2007, 27, 1189-1197.	1.2	157
138	New antimicrobial agents as therapy for resistant gram-positive cocci. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2007, 27, 3-15.	1.3	85
139	Linezolid versus Vancomycin for Prosthetic Joint Infections: a Cost Analysis. <i>Infection</i> , 2007, 35, 265-270.	2.3	8
140	Glycopeptide insensitive <i>Staphylococcus aureus</i> subdural empyema treated with linezolid and rifampicin. <i>Journal of Infection</i> , 2008, 57, 410-413.	1.7	12
141	Strategies for managing today's infections. <i>Clinical Microbiology and Infection</i> , 2008, 14, 22-31.	2.8	33

#	ARTICLE	IF	CITATIONS
142	Linezolid for the treatment of drug-resistant infections. <i>Expert Review of Anti-Infective Therapy</i> , 2008, 6, 825-848.	2.0	27
143	Benefit-Risk Assessment of Linezolid for Serious Gram-Positive Bacterial Infections. <i>Drug Safety</i> , 2008, 31, 753-768.	1.4	40
145	New antibiotic agents for bloodstream infections. <i>International Journal of Antimicrobial Agents</i> , 2008, 32, S60-S65.	1.1	26
146	Emergence and management of drug-resistant enterococcal infections. <i>Expert Review of Anti-Infective Therapy</i> , 2008, 6, 637-655.	2.0	239
147	Antibiotic Adverse Reactions and Drug Interactions. <i>Critical Care Clinics</i> , 2008, 24, 421-442.	1.0	110
148	Clinical pharmacology of linezolid: an oxazolidinone antimicrobial agent. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 479-489.	1.3	6
149	Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. <i>Lancet Infectious Diseases</i> , The, 2008, 8, 612-620.	4.6	80
150	Impact of the More-Potent Antibiotics Quinupristin-Dalfopristin and Linezolid on Outcome Measure of Patients with Vancomycin-Resistant Enterococcus Bacteremia. <i>Clinical Infectious Diseases</i> , 2008, 46, 30-36.	2.9	65
151	Medications for Extensively Drug-Resistant Tuberculosis: Back to the Future?. <i>Journal of Pharmacy Technology</i> , 2008, 24, 82-95.	0.5	0
152	Painful neuropathy with skin denervation after prolonged use of linezolid. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 97-99.	0.9	35
153	Health Care-Associated Endocarditis Caused by <i>Staphylococcus aureus</i> with Reduced Susceptibility to Vancomycin. <i>Journal of Clinical Microbiology</i> , 2008, 46, 810-813.	1.8	8
154	Short-term success, but long-term treatment failure with linezolid for enterococcal endocarditis. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 765-766.	1.5	13
155	<i>In Vitro</i> Activities of Linezolid and Tigecycline Against Methicillin-Resistant <i>Staphylococcus aureus</i> Strains. <i>Microbial Drug Resistance</i> , 2008, 14, 151-153.	0.9	14
156	Emerging Treatments for Resistant Bacterial Infections and Pathogen-Focused Therapy. <i>Infectious Diseases in Clinical Practice</i> , 2008, 16, S1-S20.	0.1	0
157	Novel Therapeutic Agents for Resistant Gram-Positive Infections. <i>Current Drug Therapy</i> , 2008, 3, 98-110.	0.2	1
158	<i>Staphylococcus aureus</i> Bloodstream Infections: Definitions and Treatment. <i>Clinical Infectious Diseases</i> , 2009, 48, S254-S259.	2.9	148
159	Enterococcus: Antimicrobial Resistance in Enterococci Epidemiology, Treatment, and Control. , 2009, , 715-733.		3
160	Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 175-180.	1.3	61

#	ARTICLE	IF	CITATIONS
161	Infectious Diseases in Critical Care Medicine. , 0, , .		2
162	Association of Pharmacokinetic and Pharmacodynamic Aspects of Linezolid with Infection Outcome. Current Drug Metabolism, 2009, 10, 2-12.	0.7	26
163	A Case of Optic Neuropathy after Shortâ€Term Linezolid Use in a Patient with Acute Lymphocytic Leukemia. Clinical Infectious Diseases, 2009, 48, e73-e74.	2.9	33
164	Daptomycin Therapy for Vancomycinâ€Resistant Enterococcal Bacteremia: A Retrospective Case Series of 30 Patients. Pharmacotherapy, 2009, 29, 792-799.	1.2	46
165	Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus: Preventing Surgical Site Infections Following Plastic Surgery. Aesthetic Surgery Journal, 2009, 29, 232-244.	0.9	25
166	Antibiotic considerations in the treatment of multidrug-resistant (MDR) pathogens: A case-based review. Journal of Hospital Medicine, 2009, 4, E8-E15.	0.7	10
167	In vitro activity of daptomycin against Staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: data from two nationwide studies. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 1209-1215.	1.3	8
168	Antimicrobial therapy for bone and joint infections. Current Infectious Disease Reports, 2009, 11, 7-13.	1.3	13
169	Linezolid: a review of safety and tolerability. Journal of Infection, 2009, 59, S59-S74.	1.7	170
170	Linezolidâ€induced purpuric medication reaction. Journal of Cutaneous Pathology, 2009, 36, 793-795.	0.7	8
171	Antibiotics for Gram-Positive Bacterial Infections: Vancomycin, Teicoplanin, Quinupristin/Dalfopristin, Oxazolidinones, Daptomycin, Dalbavancin, and Telavancin. Infectious Disease Clinics of North America, 2009, 23, 965-982.	1.9	43
172	Update on the safety of linezolid. Expert Opinion on Drug Safety, 2009, 8, 485-491.	1.0	25
173	Therapeutic options for infections due to vancomycin-resistant enterococci. Expert Opinion on Pharmacotherapy, 2009, 10, 785-796.	0.9	47
174	Peripheral Neuropathy in an Adolescent Treated With Linezolid. Pediatric Infectious Disease Journal, 2009, 28, 149-151.	1.1	22
175	A Rapid High-Performance Liquid Chromatography Method to Measure Linezolid and Daptomycin Concentrations in Human Plasma. Therapeutic Drug Monitoring, 2010, 32, 200-205.	1.0	32
176	Treatment of Resistant Enterococcal Urinary Tract Infections. Current Infectious Disease Reports, 2010, 12, 455-464.	1.3	51
177	Clinical efficacy and tolerability of linezolid in pediatric patients: A systematic review. Clinical Therapeutics, 2010, 32, 66-88.	1.1	61
178	Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study. Clinical Therapeutics, 2010, 32, 1713-1719.	1.1	67

#	ARTICLE	IF	CITATIONS
179	Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 2242-2249.	1.0	32
180	Management of multidrug-resistant enterococcal infections. <i>Clinical Microbiology and Infection</i> , 2010, 16, 555-562.	2.8	302
181	Novel pharmaceutical molecules against emerging resistant gram-positive cocci. <i>Brazilian Journal of Infectious Diseases</i> , 2010, 14, 96-108.	0.3	11
182	Compassionate Use of Linezolid for Adult Taiwanese Patients with Bone and Joint Infections. <i>Chemotherapy</i> , 2010, 56, 429-435.	0.8	11
183	Drug-induced thrombocytopenia in critically ill patients. <i>Critical Care Medicine</i> , 2010, 38, S145-S154.	0.4	63
184	Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2224-2230.	1.3	56
185	A potential role for daptomycin in enterococcal infections: what is the evidence?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1126-1136.	1.3	81
186	Linezolid treatment of shunt-related cerebrospinal fluid infections in children. <i>Journal of Neurosurgery: Pediatrics</i> , 2010, 5, 443-448.	0.8	26
187	Clinical Experience with Linezolid at a Large Academic Medical Center: A Case Series and Review of the Literature. <i>Hospital Pharmacy</i> , 2010, 45, 916-926.	0.4	3
188	Novel pharmaceutical molecules against emerging resistant gram-positive cocci. <i>Brazilian Journal of Infectious Diseases</i> , 2010, 14, 96-108.	0.3	13
189	Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 3-12.	1.1	88
190	Pharmacological Issues of Linezolid. <i>Clinical Pharmacokinetics</i> , 2010, 49, 439-447.	1.6	75
191	Use of linezolid in pediatrics: a critical review. <i>International Journal of Infectious Diseases</i> , 2010, 14, e638-e648.	1.5	38
192	Quinupristinâ€“dalfopristin versus linezolid for the treatment of vancomycin-resistant <i>Enterococcus faecium</i> bacteraemia: Efficacy and development of resistance. <i>Scandinavian Journal of Infectious Diseases</i> , 2010, 42, 491-499.	1.5	21
193	Current Concepts in Antimicrobial Therapy Against Select Gram-Positive Organisms: Methicillin-Resistant <i>Staphylococcus aureus</i> , Penicillin-Resistant <i>Pneumococci</i> , and Vancomycin-Resistant <i>Enterococci</i> . <i>Mayo Clinic Proceedings</i> , 2011, 86, 1230-1243.	1.4	115
194	Antibiotics for Gram-Positive Bacterial Infection: Vancomycin, Teicoplanin, Quinupristin/Dalfopristin, Oxazolidinones, Daptomycin, Telavancin, and Ceftaroline. <i>Medical Clinics of North America</i> , 2011, 95, 723-742.	1.1	11
195	HIGH-THROUGHPUT DETERMINATION OF LINEZOLID IN HUMAN PLASMA BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2011, 34, 436-445.	0.5	6
196	Management of infective endocarditis in children. <i>Journal of Indian College of Cardiology</i> , 2011, 1, 119-124.	0.1	0

#	ARTICLE	IF	CITATIONS
197	Design, Synthesis, and Biological Evaluation of New Cinnamic Derivatives as Antituberculosis Agents. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1449-1461.	2.9	100
198	Bacterial Infection, Antimicrobial Use, and Antibiotic-Resistant Organisms in the Pediatric Intensive Care Unit. , 2011, , 1315-1323.		0
199	Comparison of Linezolid and Daptomycin in the Treatment of Vancomycin-Resistant Enterococcal Bacteremia. <i>Infectious Diseases in Clinical Practice</i> , 2011, 19, 343-347.	0.1	13
201	The oxazolidinones: past, present, and future. <i>Annals of the New York Academy of Sciences</i> , 2011, 1241, 48-70.	1.8	223
202	Antibiotics that target protein synthesis. <i>Wiley Interdisciplinary Reviews RNA</i> , 2011, 2, 209-232.	3.2	111
203	Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. <i>Journal of Infection and Chemotherapy</i> , 2011, 17, 70-75.	0.8	83
204	Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. <i>Journal of Infection and Chemotherapy</i> , 2011, 17, 382-387.	0.8	105
205	HIGH-THROUGHPUT DETERMINATION OF LINEZOLID IN HUMAN PLASMA BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2011, 34, 591-600.	0.5	3
206	Antimicrobial Treatment of "Complicated" Intra-Abdominal Infections and The New IDSA Guidelines - A Commentary and an Alternative European Approach According to Clinical Definitions. <i>European Journal of Medical Research</i> , 2011, 16, 115.	0.9	60
207	From lead management to implanted patient management: indications to lead extraction in pacemaker and cardioverter-defibrillator systems. <i>Expert Review of Medical Devices</i> , 2011, 8, 235-255.	1.4	47
208	Immediate hematological toxicity of linezolid in healthy volunteers with different body weight: a phase I clinical trial. <i>Journal of Antibiotics</i> , 2012, 65, 175-178.	1.0	10
209	Management of infective endocarditis: challenges and perspectives. <i>Lancet, The</i> , 2012, 379, 965-975.	6.3	359
210	FDG PET Assessment of Osteomyelitis: A Review. <i>PET Clinics</i> , 2012, 7, 161-179.	1.5	7
211	Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults. <i>Clinical Infectious Diseases</i> , 2012, 54, 393-407.	2.9	373
212	Risk Factors for Thrombocytopenia in Adult Chinese Patients Receiving Linezolid Therapy. <i>Current Therapeutic Research</i> , 2012, 73, 195-206.	0.5	41
213	Polineuropatía dolorosa secundaria a tratamiento prolongado con linezolid: a propósito de un caso. <i>Neurología</i> , 2012, 27, 443-445.	0.3	1
214	Painful polyneuropathy secondary to prolonged treatment with linezolid: Presentation of a case. <i>Neurología (English Edition)</i> , 2012, 27, 443-445.	0.2	0
216	Clinical update on linezolid in the treatment of Gram-positive bacterial infections. <i>Infection and Drug Resistance</i> , 2012, 5, 87.	1.1	66

#	ARTICLE	IF	CITATIONS
217	Enterococcal Endocarditis: Can We Win the War?. <i>Current Infectious Disease Reports</i> , 2012, 14, 339-349.	1.3	46
218	Vancomycin-Resistant <i>Enterococcus</i> Infections in Solid Organ Transplantation. <i>American Journal of Transplantation</i> , 2013, 13, 59-67.	2.6	33
219	Linezolid in late-chronic prosthetic joint infection caused by gram-positive bacteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 76, 93-98.	0.8	18
220	In vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant <i>Enterococcus</i> isolates. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 77, 254-257.	0.8	40
221	Vancomycin-Resistant <i>Enterococci</i> . <i>Critical Care Clinics</i> , 2013, 29, 841-852.	1.0	46
222	Current and prospective treatments for multidrug-resistant gram-positive infections. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1919-1932.	0.9	40
223	<i>Enterococcus faecalis</i> infective endocarditis: focus on clinical aspects. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1247-1257.	0.6	51
224	Effects of Vitamin B6 Therapy for Sepsis Patients with Linezolid-Associated Cytopenias: A Retrospective Study. <i>Current Therapeutic Research</i> , 2013, 74, 26-32.	0.5	7
226	Linezolid Desensitization for a Patient with Multiple Medication Hypersensitivity Reactions. <i>Annals of Pharmacotherapy</i> , 2013, 47, e30-e30.	0.9	9
227	Virulence of Vancomycin-Resistant <i>Enterococcus faecium</i> According to Linezolid Resistance and Clinical Outbreak Status. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3923-3927.	1.4	7
228	Drug-Related Mitochondrial Optic Neuropathies. <i>Journal of Neuro-Ophthalmology</i> , 2013, 33, 172-178.	0.4	93
229	Systematic Review and Meta-Analysis of Linezolid and Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5013-5018.	1.4	87
231	Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections. <i>Drug Design, Development and Therapy</i> , 2013, 7, 243.	2.0	14
232	Clinical Management of <i>Staphylococcus aureus</i> Bacteremia. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1330.	3.8	350
233	Tedizolid Phosphate for the Management of Acute Bacterial Skin and Skin Structure Infections: Safety Summary. <i>Clinical Infectious Diseases</i> , 2014, 58, S51-S57.	2.9	36
234	Optimizing therapy for vancomycin-resistant enterococcal bacteremia in children. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 517-527.	1.3	13
235	Novel Insights into Urinary Tract Infections and their Management. , 2014, , .		0
237	Nutritional and Toxic Optic Neuropathies. , 2014, , 177-207.		4

#	ARTICLE	IF	CITATIONS
238	Reduction of linezolid-associated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 79, 93-97.	0.8	25
239	Efficacy and Safety of Linezolid in Treating Gram-Positive Bacterial Infection in the Elderly: A Retrospective Study. <i>Indian Journal of Microbiology</i> , 2014, 54, 104-107.	1.5	8
241	Treatment of Infections Due to Resistant <i>Staphylococcus aureus</i> . <i>Methods in Molecular Biology</i> , 2014, 1085, 259-309.	0.4	29
242	What's New in the Treatment of Enterococcal Endocarditis?. <i>Current Infectious Disease Reports</i> , 2014, 16, 431.	1.3	41
243	Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2334-2343.	1.4	96
244	Optic Nerve Disorders. , 2014, , .		7
245	Microbiological Spectrum and Antibiotic Sensitivity in Endophthalmitis. <i>Ophthalmology</i> , 2014, 121, 1634-1642.	2.5	164
246	Antibiotics and Bacterial Resistance in the 21st Century. <i>Perspectives in Medicinal Chemistry</i> , 2014, 6, PMC.S14459.	4.6	1,268
247	Non-inferiority designs and novel antimicrobials. <i>Clinical Investigation</i> , 2014, 4, 387-389.	0.0	0
248	Full Characterization of Linezolid and Its Synthetic Precursors by Solid-State Nuclear Magnetic Resonance Spectroscopy and Mass Spectrometry. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 3883-3892.	1.6	7
249	Risk factors for <i>Candida</i> colonization and Co-colonization with multi-drug resistant organisms at admission. <i>Antimicrobial Resistance and Infection Control</i> , 2015, 4, 46.	1.5	17
250	A Triad of Linezolid Toxicity: Hypoglycemia, Lactic Acidosis, and Acute Pancreatitis. <i>Baylor University Medical Center Proceedings</i> , 2015, 28, 466-468.	0.2	16
251	Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. <i>Infection and Drug Resistance</i> , 2015, 8, 217.	1.1	338
252	Polymorphic solidification of Linezolid confined in electrospun PCL fibers for controlled release in topical applications. <i>International Journal of Pharmaceutics</i> , 2015, 490, 32-38.	2.6	24
253	Therapeutic options for vancomycin-resistant enterococcal bacteremia. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 363-377.	2.0	30
254	Colistin-related thrombocytopenia. <i>Platelets</i> , 2015, 26, 812-813.	1.1	2
255	Enterococcal endocarditis revisited. <i>Future Microbiology</i> , 2015, 10, 1215-1240.	1.0	32
257	Acute bone and joint infections in children and therapeutic options. <i>Journal of Pediatric Infectious Diseases</i> , 2015, 02, 193-203.	0.1	1

#	ARTICLE	IF	CITATIONS
258	SecA: a potential antimicrobial target. <i>Future Medicinal Chemistry</i> , 2015, 7, 989-1007.	1.1	23
259	Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications. <i>Circulation</i> , 2015, 132, 1435-1486.	1.6	2,218
260	The Enterococci. , 2015, , 717-730.		0
261	Vancomycin-Resistant Enterococcal Bacteremia Pharmacotherapy. <i>Annals of Pharmacotherapy</i> , 2015, 49, 69-85.	0.9	40
262	Design, syntheses and evaluation of 4-oxo-5-cyano thiouracils as SecA inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 105-117.	1.4	23
264	Managing drug-resistant organisms in acute care. <i>Nurs Crit Care (Amblar)</i> , 2016, 11, 16-22.	0.3	0
265	Linezolid Induced Reversible Peripheral Neuropathy. <i>American Journal of Therapeutics</i> , 2016, 23, e1839-e1841.	0.5	8
266	Linezolid-Induced Thrombocytopenia Is Caused by Suppression of Platelet Production & Phosphorylation of Myosin Light Chain 2. <i>Biological and Pharmaceutical Bulletin</i> , 2016, 39, 1846-1851.	0.6	24
267	Managing drug-resistant organisms in acute care. <i>Nurse Practitioner</i> , 2016, 41, 38-44.	0.2	0
268	A Clinician's Guide to the Treatment of Vancomycin Resistant Enterococci Bacteremia and Endocarditis. <i>Current Treatment Options in Infectious Diseases</i> , 2016, 8, 194-207.	0.8	1
269	Treating Central Catheter-Associated Bacteremia Due to Methicillin-Resistant <i>Staphylococcus aureus</i> : Beyond Vancomycin. <i>Critical Care Nurse</i> , 2016, 36, 46-57.	0.5	1
270	Identification of 5,6-dihydroimidazo[2,1-b]thiazoles as a new class of antimicrobial agents. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5633-5638.	1.4	14
271	Linezolid desensitization in a pediatric patient. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 117, 198.	0.5	3
272	Assessing outcomes of adult oncology patients treated with linezolid versus daptomycin for bacteremia due to vancomycin-resistant <i>Enterococcus</i> . <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 212-218.	0.5	11
273	<i>Mycobacterium tuberculosis</i> Mutations Associated with Reduced Susceptibility to Linezolid. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2542-2544.	1.4	49
274	Safety profiles of old and new antimicrobials for the treatment of MRSA infections. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 467-481.	1.0	29
275	Safety and efficacy of commonly used antimicrobial agents in the treatment of enterococcal infections: a review. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 153-167.	1.0	9
276	Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 628-633.	1.1	25

#	ARTICLE	IF	CITATIONS
277	Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci. <i>Infection</i> , 2016, 44, 273-281.	2.3	15
278	The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection. <i>Surgical Infections</i> , 2017, 18, 1-76.	0.7	382
279	Identification of the cfr methyltransferase gene in <i>Enterococcus faecalis</i> isolated from swine: First report in Brazil. <i>Journal of Global Antimicrobial Resistance</i> , 2017, 8, 192-193.	0.9	5
280	Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1758-1772.	1.1	74
281	Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference. <i>World Journal of Emergency Surgery</i> , 2017, 12, 22.	2.1	130
282	Characterization of Neurologic and Ophthalmologic Safety of Oral Administration of Tedizolid for Up to 21 Days in Healthy Volunteers. <i>American Journal of Therapeutics</i> , 2017, 24, e227-e233.	0.5	15
283	Determination of minor quantities of linezolid polymorphs in a drug substance and tablet formulation by powder X-ray diffraction technique. <i>Powder Diffraction</i> , 2017, 32, 78-85.	0.4	13
284	Nanoparticles/thermosensitive hydrogel reinforced with chitin whiskers as a wound dressing for treating chronic wounds. <i>Journal of Materials Chemistry B</i> , 2017, 5, 3172-3185.	2.9	78
285	Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects. <i>Clinical Therapeutics</i> , 2017, 39, 1849-1857.	1.1	7
286	Treatment of Vancomycin-Resistant Enterococci: Focus on Daptomycin. <i>Current Infectious Disease Reports</i> , 2017, 19, 33.	1.3	7
287	Pharmacokinetics, Pharmacodynamics, and Tolerability of Single-Dose Oral LCB01-0371, a Novel Oxazolidinone with Broad-Spectrum Activity, in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	13
288	Endocarditis and Other Intravascular Infections. , 2018, , 261-270.e3.		1
289	Brain Abscess Showing a Lack of Restricted Diffusion and Successfully Treated with Linezolid. <i>Brain Tumor Research and Treatment</i> , 2018, 6, 92.	0.4	5
290	Linezolid-induced pancytopenia. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-225480.	0.2	3
291	Multiple-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral LCB01-0371 in Healthy Male Volunteers. <i>Clinical Therapeutics</i> , 2018, 40, 2050-2064.	1.1	9
292	Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature. <i>Drug Resistance Updates</i> , 2018, 40, 25-39.	6.5	165
293	Impact on Public Health of the Spread of High-Level Resistance to Gentamicin and Vancomycin in Enterococci. <i>Frontiers in Microbiology</i> , 2018, 9, 3073.	1.5	44
294	27 Traumatic Brain Injury and Infection. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
295	Reversible recurrent profound thrombocytopenia due to linezolid in a patient with multi-drug resistant tuberculosis. <i>Medicine (United States)</i> , 2018, 97, e11997.	0.4	4
296	Antibacterial and Antifungal Agents: The Challenges of Antimicrobial-Resistant Infections in Immunocompromised Hosts. , 2018, , 297-315.		3
297	Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea. <i>Annals of Laboratory Medicine</i> , 2018, 38, 563-568.	1.2	60
298	Linezolid: a review of its properties, function, and use in critical care. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1759-1767.	2.0	221
299	Combating resistant enterococcal infections: a pharmacotherapy review. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 979-992.	0.9	62
300	Neurological and Psychiatric Adverse Effects of Antimicrobials. <i>CNS Drugs</i> , 2019, 33, 727-753.	2.7	25
301	Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3588-3595.	1.3	35
302	Current Evidence on Oral Antibiotics for Infective Endocarditis: A Narrative Review. <i>Cardiology and Therapy</i> , 2019, 8, 167-177.	1.1	8
303	Endovascular Infections and Endocarditis. , 2019, , 273-290.		0
304	Pharmacokinetics, toxicity and clinical efficacy of linezolid in Japanese pediatric patients. <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 979-986.	0.8	14
305	Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia. <i>Therapeutic Advances in Infectious Disease</i> , 2019, 6, 204993611982896.	1.1	13
306	AMELIORATIVE EFFECT OF PHOENIX DACTYLIFERA ON ADVERSE EFFECTS OF LINEZOLID IN MALE ALBINO RATS. <i>International Journal of Applied Pharmaceutics</i> , 0, , 9-13.	0.3	0
307	<p>>Pharmacodynamics Of Linezolid-Plus-Fosfomycin Against Vancomycin-Susceptible And -Resistant Enterococci In Vitro And In Vivo Of A >Galleria mellonella> Larval Infection Model</p>>. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 3497-3505.	1.1	12
308	Antimicrobial-resistant CC17 <i>Enterococcus faecium</i> : The past, the present and the future. <i>Journal of Global Antimicrobial Resistance</i> , 2019, 16, 36-47.	0.9	106
309	Single-dose Intravenous Safety, Tolerability, and Pharmacokinetics and Absolute Bioavailability ofALCB01-0371. <i>Clinical Therapeutics</i> , 2019, 41, 92-106.	1.1	8
310	Linezolid induced optic neuropathy in a child treated for extensively drug resistant tuberculosis: A case report and review of literature. <i>Saudi Journal of Ophthalmology</i> , 2019, 33, 188-191.	0.3	6
311	Early Oral Switch to Linezolid for Low-risk Patients With <i>Staphylococcus aureus</i> Bloodstream Infections: A Propensity-matched Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 381-387.	2.9	50
312	A retrospective cohort study to screen linezolid-induced thrombocytopenia in adult patients hospitalized in the Midwestern Region of Brazil. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 230-237.	0.1	13

#	ARTICLE	IF	CITATIONS
313	Current Concepts in Ophthalmology. , 2020, , .		1
314	Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, S16-S116.	2.0	107
315	Linezolid to treat urinary tract infections caused by vancomycin-resistant Enterococcus. SAGE Open Medicine, 2020, 8, 205031212097074.	0.7	5
316	Antimicrobial resistance genes in bacteria from animal-based foods. Advances in Applied Microbiology, 2020, 112, 143-183.	1.3	25
317	A Narrative Review of Early Oral Stepdown Therapy for the Treatment of Uncomplicated Staphylococcus aureus Bacteremia: Yay or Nay?. Open Forum Infectious Diseases, 2020, 7, ofaa151.	0.4	17
318	Dynamic Changes of Staphylococcus aureus Susceptibility to Vancomycin, Teicoplanin, and Linezolid in a Central Teaching Hospital in Shanghai, China, 2008â€“2018. Frontiers in Microbiology, 2020, 11, 908.	1.5	25
319	The interplay between acute bacterial skin and skin structure infections and depression. Current Opinion in Infectious Diseases, 2020, 33, 1.	1.3	3
320	Consensus Report on Diagnosis, Treatment and Prevention of Infective Endocarditis by Turkish Society of Cardiovascular Surgery (TSCVS), Turkish Society of Clinical Microbiology and Infectious Diseases (KLIMIK), Turkish Society of Cardiology (TSC), Turkish Society of Nuclear Medicine (TSNM), Turkish Society of Radiology (TSR), Turkish Dental Association (TDA) and Federation of Turkish Pathology Societies (TURKPATH) Cardiovascular System Study Group. Turkish Journal of Thoracic and Cardiovascular Surgery, 2020, 28, 2-42.	0.2	5
321	Use of Linezolid in the treatment of surgical infectious complications under antibiotic resistance. Perioperaciina Medicina, 2021, 3, 34-39.	0.1	0
322	External Evaluation of Population Pharmacokinetics and Pharmacodynamics in Linezolid-Induced Thrombocytopenia: The Transferability of Published Models to Different Hospitalized Patients. Therapeutic Drug Monitoring, 2021, 43, 271-278.	1.0	9
323	Classification Tree Analysis Based On Machine Learning for Predicting Linezolid-Induced Thrombocytopenia. Journal of Pharmaceutical Sciences, 2021, 110, 2295-2300.	1.6	5
324	Common and Rare Hematological Manifestations and Adverse Drug Events during Treatment of Active TB: A State of Art. Microorganisms, 2021, 9, 1477.	1.6	16
326	Hospital Pharmacometrics for Optimal Individual Administration of Antimicrobial Agents for Anti-methicillin-resistant <i>Staphylococcus aureus</i> Infected Patients. Biological and Pharmaceutical Bulletin, 2021, 44, 1174-1183.	0.6	1
327	Exploratory Cost-Effectiveness Analysis for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: Is Linezolid or Daptomycin Favored Over Vancomycin?. Clinical Drug Investigation, 2021, 41, 885-894.	1.1	3
328	Enterococcal Infections in Adults. , 2017, , 811-818.		3
329	Linezolid and Other Oxazolidinones. , 2015, , 406-409.e2.		7
330	Performance of commercial methods for linezolid susceptibility testing of Enterococcus faecium and Enterococcus faecalis. Journal of Antimicrobial Chemotherapy, 2020, 75, 2587-2593.	1.3	8
331	The epidemiology and molecular characteristics of linezolid-resistant Staphylococcus capitis in Huashan Hospital, Shanghai. Journal of Medical Microbiology, 2020, 69, 1079-1088.	0.7	8

#	ARTICLE	IF	CITATIONS
332	A case of fatal daptomycin-resistant, vancomycin-resistant enterococcal infective endocarditis in end-stage kidney disease. JMM Case Reports, 2015, 2, .	1.3	4
333	Painful neuropathy with skin denervation after prolonged use of linezolid. BMJ Case Reports, 2009, 2009, bcr0820080702-bcr0820080702.	0.2	1
334	Lactic Acidosis and Thrombocytopenia Associated with Linezolid Therapy: A Case Report. American Journal of Case Reports, 2018, 19, 1117-1120.	0.3	5
336	Osteomyelitis in Long Bones. Journal of Bone and Joint Surgery - Series A, 2004, 86, 2305-2318.	1.4	309
337	Update on the appropriate use of linezolid in clinical practice. Therapeutics and Clinical Risk Management, 2006, 2, 455-464.	0.9	19
338	Multidrug-Resistant Gram-Positive Bacterial Infections. Korean Journal of Medicine, 2015, 88, 487.	0.1	3
339	Oral Agents for the Treatment of Orthopedic Infections Caused by Methicillin-resistant Staphylococci. Infection and Chemotherapy, 2011, 43, 322.	1.0	3
341	Enterococci: Resistance Update and Treatment Options. Infectious Disease and Therapy, 2007, , 89-110.	0.0	0
342	Endocarditis and Intravascular Infections. , 2008, , 269-277.		2
344	Resistance to Linezolid. , 2009, , 247-257.		1
345	ENTEROCOCCAL AND VIRIDANS STREPTOCOCCAL INFECTIONS. , 2009, , 1258-1288.		1
346	Antibiotic Resistance of Non-Pneumococcal Streptococci and Its Clinical Impact. , 2009, , 695-714.		1
347	The Efficacy of Linezolid for Methicillin-resistant Staphylococcus aureus Infectious Endocarditis. Japanese Journal of Cardiovascular Surgery, 2009, 38, 280-283.	0.0	2
348	Adverse Reactions to Antibiotics inCriticalCare. Infectious Disease and Therapy, 2009, , 542-556.	0.0	0
349	Adverse Reactions to Antibiotics inCriticalCare. Infectious Disease and Therapy, 2009, , 542-556.	0.0	0
350	Present and Emerging Therapies for the Treatment of Drug-resistant Infections: Focus on Linezolid. Clinical Medicine Reviews in Therapeutics, 0, 2, 59-78.	0.4	0
351	Analysis of the molecular epidemiology and antibiotic sensitivity of vancomycin-resistant enterococci. Gaziantep Medical Journal, 2011, 17, 82.	0.2	1
352	PrÄvention und Antibiotikatherapie postoperativer Komplikationen. , 2011, , 223-232.		0

#	ARTICLE	IF	CITATIONS
375	Structural basis for context-specific inhibition of translation by oxazolidinone antibiotics. <i>Nature Structural and Molecular Biology</i> , 2022, 29, 162-171.	3.6	31
376	Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 359-386.	1.5	25
377	Linezolid for infective endocarditis. <i>Medicine (United States)</i> , 2021, 100, e27597.	0.4	5
378	Immediate and Delayed Hypersensitivity Reactions to Antibiotics: Aminoglycosides, Clindamycin, Linezolid, and Metronidazole. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 463-475.	2.9	16
380	Linezolid induced thrombocytopenia in critically ill patients: Risk factors and development of a machine learning-based prediction model. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1249-1254.	0.8	10
381	Molecular Basis of Non-β-Lactam Antibiotics Resistance in <i>Staphylococcus aureus</i> . <i>Antibiotics</i> , 2022, 11, 1378.	1.5	11
382	Endocarditis and Other Intravascular Infections. , 2023, , 269-278.e4.		0
383	Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopenia. <i>European Journal of Clinical Pharmacology</i> , 0, , .	0.8	1
384	Distribution and Antibiotic Resistance Characteristics of Bacteria Isolated from Blood Culture in a Teaching Hospital in Vietnam During 2014–2021. <i>Infection and Drug Resistance</i> , 0, Volume 16, 1677-1692.	1.1	5
385	Treatment of <i>Enterococcus faecalis</i> Infective Endocarditis: A Continuing Challenge. <i>Antibiotics</i> , 2023, 12, 704.	1.5	2
386	Risk factors for mortality after linezolid treatment of vancomycin-resistant <i>Enterococcus</i> bloodstream infection. <i>International Journal of Infectious Diseases</i> , 2023, 129, 96-102.	1.5	1
387	Treatment Strategies to Combat Multidrug Resistance (MDR) in Bacteria. , 2023, , 79-100.		0
388	Antibacterial drugs. , 2023, , 119-148.		0